{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:17:22Z","timestamp":1757618242721,"version":"3.44.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This multicenter, double-blind, parallel-group, randomised controlled phase III study evaluated the efficacy and safety of the Allisartan Isoproxil 240\u2009mg \/Amlodipine 5\u2009mg (ALI\/AML) combination compared with ALI 240\u2009mg monotherapy in patients with mild-to-moderate essential hypertension. Patients aged 18 to 70 years with mean sitting systolic blood pressure (msSBP) between 140 and &lt;180\u2009mmHg and mean sitting diastolic blood pressure (msDBP) between 90 and &lt;110\u2009mmHg were randomised 1:1 to receive ALI\/AML or ALI once-daily for 12 weeks after a 4-week treatment with ALI, followed by an open-label extension period with ALI\/AML up to week 52. A total of 199 patients were randomised (ALI\/AML: n\u2009=\u200999, ALI: n\u2009=\u2009100) with 169 completing the study. Baseline characteristics were comparable between groups. After 12 weeks of randomisation, the reduction in msSBP (primary endpoint) was significantly greater in the ALI\/AML group vs the ALI group (\u221218.3 vs. \u22129.3\u2009mmHg, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Reductions in msDBP (\u22126.0 vs. \u22121.9\u2009mmHg, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and 24-hour mean ambulatory systolic\/diastolic blood pressure (\u221219.9\/\u221210.1 vs. \u22126.9\/\u22124.2\u2009mmHg) were more pronounced in the ALI\/AML group. Additionally, a greater proportion of patients achieved the BP response and target office BP in the ALI\/AML group compared to the ALI group (53.6% vs. 25.5%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; 40.2% vs. 20.4%, <jats:italic>p<\/jats:italic>=0.0026). AML\/ALI combination was generally safe and well tolerated, with sustained efficacy up to 52 weeks. The study concluded that ALI\/AML offers a convenient, single-pill option for effective BP reduction in hypertensive patients.<\/jats:p>","DOI":"10.1038\/s41371-025-01035-3","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T02:54:55Z","timestamp":1750128895000},"page":"500-508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Allisartan Isoproxil\/Amlodipine in Patients with Essential Hypertension: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomised study"],"prefix":"10.1038","volume":"39","author":[{"given":"Hongjie","family":"Chi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zichen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0806-0508","authenticated-orcid":false,"given":"Xiangmin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"1035_CR1","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1161\/HYPERTENSIONAHA.119.12958","volume":"74","author":"Y Li","year":"2019","unstructured":"Li Y, Thijs L, Zhang ZY, Asayama K, Hansen TW, Boggia J, et al. Opposing Age-Related Trends in Absolute and Relative Risk of Adverse Health Outcomes Associated With Out-of-Office Blood Pressure. Hypertension. 2019;74:1333\u201342.","journal-title":"Hypertension"},{"key":"1035_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2019.9811","volume":"322","author":"WY Yang","year":"2019","unstructured":"Yang WY, Melgarejo JD, Thijs L, Zhang ZY, Boggia J, Wei FF, et al. Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes. JAMA. 2019;322:409\u201320.","journal-title":"JAMA"},{"key":"1035_CR3","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","volume":"383","author":"E Rapsomaniki","year":"2014","unstructured":"Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899\u2013911.","journal-title":"Lancet"},{"key":"1035_CR4","first-page":"33","volume":"10","author":"WJ Tu","year":"2023","unstructured":"Tu WJ, Wang LD. Special Writing Group of China Stroke Surveillance Report. China stroke surveillance report 2021. Mil Med Res. 2023;10:33.","journal-title":"Mil Med Res"},{"key":"1035_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.26599\/1671-5411.2024.06.001","volume":"21","author":"Q Hua","year":"2024","unstructured":"Hypertension Branch of Chinese Geriatrics Society, Beijing Hypertension Association, National Clinical Research Center of the Geriatric Diseases, Hua Q, Fan L, Wang ZW, Li J. 2023 Guideline for the management of hypertension in the elderly population in China. J Geriatr Cardiol. 2024;21:589\u2013630.","journal-title":"J Geriatr Cardiol"},{"key":"1035_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223\u201337.","journal-title":"Nat Rev Nephrol"},{"key":"1035_CR7","first-page":"669","volume":"36","author":"The WCOTROCHADIC","year":"2023","unstructured":"The WCOTROCHADIC. Report on Cardiovascular Health and Diseases in China 2022: an Updated Summary. Biomed Environ Sci. 2023;36:669\u2013701.","journal-title":"Biomed Environ Sci"},{"key":"1035_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26599\/1671-5411.2025.01.008","volume":"22","author":"JG Wang","year":"2025","unstructured":"Wang JG. Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision). J Geriatr Cardiol. 2025;22:1\u2013149.","journal-title":"J Geriatr Cardiol"},{"key":"1035_CR9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/jch.14236","volume":"23","author":"N Verma","year":"2021","unstructured":"Verma N, Rastogi S, Chia YC, Siddique S, Turana Y, Cheng HM, et al. Non-pharmacological management of hypertension. J Clin Hypertens (Greenwich). 2021;23:1275\u201383.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1035_CR10","volume":"4","author":"JM Wright","year":"2018","unstructured":"Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev. 2018;4:CD001841.","journal-title":"Cochrane Database Syst Rev"},{"key":"1035_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejim.2024.04.011","volume":"126","author":"A Coca","year":"2024","unstructured":"Coca A, Whelton SP, Camafort M, L\u00f3pez-L\u00f3pez JP, Yang E. Single-pill combination for treatment of hypertension: Just a matter of practicality or is there a real clinical benefit? Eur J Intern Med. 2024;126:16\u201325.","journal-title":"Eur J Intern Med"},{"key":"1035_CR12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","volume":"77","author":"G Parati","year":"2021","unstructured":"Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis. Hypertension. 2021;77:692\u2013705.","journal-title":"Hypertension"},{"key":"1035_CR13","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1016\/j.jacc.2019.03.507","volume":"73","author":"G Bakris","year":"2019","unstructured":"Bakris G, Ali W, Parati G. ACC\/AHA Versus ESC\/ESH on Hypertension Guidelines: JACC Guideline Comparison. J Am Coll Cardiol. 2019;73:3018\u201326.","journal-title":"J Am Coll Cardiol"},{"key":"1035_CR14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/08037051.2018.1557365","volume":"28","author":"B Williams","year":"2019","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension [published correction appears in. Blood Press. 2019;28:74.","journal-title":"Blood Press"},{"key":"1035_CR15","doi-asserted-by":"publisher","first-page":"579.e1","DOI":"10.1016\/j.jash.2018.06.010","volume":"12","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Soc Hypertens. 2018;12:579.e1\u2013579.e73. 2017","journal-title":"J Am Soc Hypertens."},{"key":"1035_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/ajh\/hpad055","volume":"36","author":"H Wang","year":"2023","unstructured":"Wang H, Xi Y, Chen Y, Wang L, Yang F, Lu X, et al. Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension. Am J Hypertens. 2023;36:561\u20137.","journal-title":"Am J Hypertens"},{"key":"1035_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102736","volume":"74","author":"JF Huang","year":"2024","unstructured":"Huang JF, Zhang DY, An DW, Li MX, Liu CY, Feng YQ, et al. Efficacy of antihypertensive treatment for target organ protection in patients with masked hypertension (ANTI-MASK): a multicentre, double-blind, placebo-controlled trial. Eclinical Medicine. 2024;74:102736.","journal-title":"Eclinical Medicine"},{"key":"1035_CR18","doi-asserted-by":"publisher","first-page":"e0117560","DOI":"10.1371\/journal.pone.0117560","volume":"10","author":"Y Li","year":"2015","unstructured":"Li Y, Li XH, Huang ZJ, Yang GP, Zhang GG, Zhao SP, et al. A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk. PLoS One. 2015;10:e0117560.","journal-title":"PLoS One"},{"key":"1035_CR19","unstructured":"Bulsara KG, Patel P, Cassagnol M Amlodipine. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 April 21. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519508\/."},{"key":"1035_CR20","unstructured":"Wenjie Y Comparative Efficacy of Amlodipine Alone Versus Amlodipine Combined with Valsartan in Patients with Coronary Heart Disease and Hypertension. Altern Ther Health Med. 2024 Jun 14:AT10646."},{"key":"1035_CR21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/jch.12771","volume":"18","author":"C Chi","year":"2016","unstructured":"Chi C, Tai C, Bai B, Yu S, Karamanou M, Wang J, et al. Angiotensin System Blockade Combined With Calcium Channel Blockers Is Superior to Other Combinations in Cardiovascular Protection With Similar Blood Pressure Reduction: A Meta-Analysis in 20,451 Hypertensive Patients. J Clin Hypertens (Greenwich). 2016;18:801\u20138.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1035_CR22","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/jch.14570","volume":"24","author":"KC Sung","year":"2022","unstructured":"Sung KC, Sung JH, Cho EJ, Ahn JC, Han SH, Kim W, et al. Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial. J Clin Hypertens (Greenwich). 2022;24:1298\u2013309.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1035_CR23","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","volume":"398","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet. 2021;398:1053\u201364.","journal-title":"Lancet"},{"key":"1035_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.medcli.2023.12.023","volume":"163","author":"A De la Sierra","year":"2024","unstructured":"De la Sierra A. Ambulatory blood pressure monitoring. Current status and future perspectives. Monitorizaci\u00f3n ambulatoria de la presi\u00f3n arterial. Situaci\u00f3n actual y perspectivas futuras. Med Clin (Barc). 2024;163:25\u201331.","journal-title":"Med Clin (Barc)"},{"key":"1035_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/jhh.2009.9","volume":"23","author":"RH Fagard","year":"2009","unstructured":"Fagard RH, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. J Hum Hypertens. 2009;23:645\u201353.","journal-title":"J Hum Hypertens"},{"key":"1035_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2362880","volume":"56","author":"J Liu","year":"2024","unstructured":"Liu J, Chen W, Shao S, Chen Y, Wang H, Xi Y, et al. Efficacy of angiotensin receptor blockers for nocturnal blood pressure reduction: a systematic review and meta-analysis. Ann Med. 2024;56:2362880.","journal-title":"Ann Med"},{"key":"1035_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/jch.14757","volume":"26","author":"J Liu","year":"2024","unstructured":"Liu J, Li Y, Zhang X, Bu P, Du X, Fang L, et al. Management of nocturnal hypertension: An expert consensus document from Chinese Hypertension League. J Clin Hypertens (Greenwich). 2024;26:71\u201383.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1035_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/11538850-000000000-00000","volume":"10","author":"SG Chrysant","year":"2010","unstructured":"Chrysant SG. The role of Angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies. Am J Cardiovasc Drugs. 2010;10:315\u201320.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1035_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11739-023-03427-0","volume":"19","author":"L De Nicola","year":"2024","unstructured":"De Nicola L, Ferraro PM, Montagnani A, Pontremoli R, Dentali F, Sesti G. Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors. Intern Emerg Med. 2024;19:295\u2013306.","journal-title":"Intern Emerg Med"},{"key":"1035_CR30","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/jch.12133","volume":"15","author":"EM Roth","year":"2013","unstructured":"Roth EM, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Olmesartan\/amlodipine\/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis. J Clin Hypertens (Greenwich). 2013;15:584\u201392.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1035_CR31","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/j.1742-1241.2010.02480.x","volume":"64","author":"TR Smith","year":"2010","unstructured":"Smith TR, Glazer RD, Koren MJ, Wernsing M, Zhang Y. Combination therapy with amlodipine\/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study. Int J Clin Pract. 2010;64:1367\u201374.","journal-title":"Int J Clin Pract"},{"key":"1035_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000443769","volume":"3","author":"M Kuwabara","year":"2016","unstructured":"Kuwabara M. Hyperuricemia, Cardiovascular Disease, and Hypertension. Pulse (Basel). 2016;3:242\u201352.","journal-title":"Pulse (Basel)"},{"key":"1035_CR33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/jch.14773","volume":"26","author":"N Sun","year":"2024","unstructured":"Sun N, Wang H. Effects of allisartan-isoproxil-based combination antihypertensive regimen in hypertensive patients with microalbuminuria or hyperuricemia. J Clin Hypertens (Greenwich). 2024;26:241\u201350.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1035_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/08037051.2019.1608134","volume":"28","author":"V Pallar\u00e9s-Carratal\u00e1","year":"2019","unstructured":"Pallar\u00e9s-Carratal\u00e1 V, Bonig-Trigueros I, Palaz\u00f3n-Bru A, Esteban-Giner MJ, Gil-Guill\u00e9n VF, Giner-Galva\u00f1 V. Clinical inertia in hypertension: a new holistic and practical concept within the cardiovascular continuum and clinical care process. Blood Press. 2019;28:217\u201328.","journal-title":"Blood Press"},{"key":"1035_CR35","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/HYPERTENSIONAHA.118.11308","volume":"72","author":"F Rea","year":"2018","unstructured":"Rea F, Corrao G, Merlino L, Mancia G. Initial Antihypertensive Treatment Strategies and Therapeutic Inertia. Hypertension. 2018;72:846\u201353.","journal-title":"Hypertension"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01035-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01035-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01035-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:43:34Z","timestamp":1757187814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01035-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["1035"],"URL":"https:\/\/doi.org\/10.1038\/s41371-025-01035-3","relation":{},"ISSN":["1476-5527"],"issn-type":[{"type":"electronic","value":"1476-5527"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"15 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Xiaojuan Lian, Yuanyuan Chen, Yan Chen, Hao Tang, Zichen Liu, and Peng Mi are employees of Shenzhen Salubris Pharmaceuticals Co., LTD. Other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of the Beijing Chaoyang Hospital affiliated with the Capital Medical University(No. 2020-Medicine-89-3); prior to study enrollment and any of the study procedures, written informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All authors critically reviewed and approved the publication of the final paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}